TABLE 1.
Baseline characteristics of two groups.
| Variables | AC + I (n = 35) | AC (n = 66) | X 2 | p |
|---|---|---|---|---|
| Gender | ||||
| Male | 20 | 36 | ||
| Female | 15 | 30 | 0.062 | 0.803 |
| Age (years) | ||||
| ≤55 | 23 | 40 | ||
| >55 | 12 | 26 | 0.254 | 0.614 |
| Tumor location a | ||||
| iCCA | 20 | 44 | ||
| pCCA | 14 | 16 | ||
| dCCA | 1 | 6 | 3.522 | 0.172 |
| Tumor differentiation | ||||
| Low | 3 | 8 | ||
| Moderate | 29 | 55 | ||
| High | 3 | 3 | 0.889 | 0.641 |
| Microvascular invasion | ||||
| Absence | 23 | 42 | ||
| Presence | 12 | 24 | 0.043 | 0.836 |
| Perineural invasion | ||||
| Absence | 18 | 30 | ||
| Presence | 17 | 36 | 0.327 | 0.567 |
| T stage | ||||
| 1 | 14 | 30 | ||
| 2 | 16 | 23 | ||
| 3 | 3 | 10 | ||
| 4 | 2 | 3 | 1.688 | 0.640 |
| Lymph node metastasis | ||||
| Absence | 22 | 48 | ||
| Presence | 13 | 18 | 0.539 | 0.463 |
| Preoperative CEA (ng/mL) | ||||
| ≤5.00 | 26 | 42 | ||
| >5.00 | 9 | 24 | 1.179 | 0.278 |
| Preoperative Ca19‐9 (U/mL) | ||||
| ≤37.00 | 12 | 17 | ||
| >37.00 | 23 | 49 | 0.813 | 0.367 |
| Preoperative TBIL (μmol/L) | ||||
| ≤17.1 | 21 | 37 | ||
| >17.1 | 14 | 29 | 0.145 | 0.703 |
| HbsAg | ||||
| Negative | 25 | 47 | ||
| Positive | 10 | 19 | 0.001 | 0.982 |
| Chemotherapy regimens b | ||||
| GX | 14 | 27 | ||
| X | 21 | 39 | 0.008 | 0.929 |
a
Tumor location: cholangiocarcinoma (CCA) is best classified according to the primary, anatomic subtype as intrahepatic CCA (iCCA), perihilar CCA (pCCA), and distal CCA (dCCA).
b
Chemotherapy regimens: gemcitabine + capecitabine (GX); capecitabine monotherapy (X).